Monte Rosa Therapeutics, Inc. (GLUE)

5,60 -0,34 (-5,72%) Börsenschluss: 04:00PM EDT

Monte Rosa Therapeutics, Inc.

321 Harrison Avenue
Suite 900
Boston, MA 02118
United States
(617) 949-2643
https://www.monterosatx.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 133

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Dr. Markus Warmuth M.D.	President, CEO & Director	924,6k	N/A	1971
Dr. Owen B. Wallace Ph.D.	Chief Scientific Officer	644,6k	N/A	1970
Dr. Filip Janku M.D., Ph.D.	Chief Medical Officer	713,2k	N/A	1974
Ms. Jennifer Champoux	Chief People & Operations Officer	N/A	N/A	N/A
Dr. Sharon Townson Ph.D.	Chief Technology Officer	N/A	N/A	1975
Dr. John C. Castle Ph.D.	Chief Data & Information Officer	N/A	N/A	1972
Mr. Andrew Funderburk	Senior VP and Head of IR & Strategic Finance	N/A	N/A	N/A
Mr. Philip Nickson J.D., Ph.D.	General Counsel	N/A	N/A	1979
Mr. Magnus Walter DPHIL	Senior Vice President of Drug Discovery	N/A	N/A	N/A
Mr. Edmund Dunn	Vice President & Corporate Controller	N/A	N/A	1966

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases. It also develops CDK2 to treat ovarian, uterine, and breast cancers. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.

Corporate Governance

Monte Rosa Therapeutics, Inc.s ISS Governance QualityScore, Stand 1. Mai 2024, lautet 9. Die grundlegenden Scores sind Audit: 9, Vorstand: 9, Shareholderrechte: 8, Kompensation: 8.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.